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1. Introduction  
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disease of 
unknown etiology. The pathology involves a degeneration of dopaminergic neurons of the 
substantia nigra with consequent dopamine (DA) deficiency and neurodegeneration of 
striatal neurons.  
The most effective treatments target compensation for the DA deficit. Among the different 
strategies applied, the most used is pharmacological substitutive treatment with levodopa 
(L-DOPA). Nevertheless, all current treatments may be considered palliative and not 
curative. 
Here we review the latest advances in research and preclinical investigation in cell 
restorative therapy by using slice tissue cultures as a model of PD. This chapter describes in 
detail the main organotypic models used to study the cellular and molecular mechanisms 
leading to dopaminergic degeneration. In particular, we move from the simplest 
organotypic co-cultured model of the substantia nigra-striatum-cortex to the unique slice of 
nigro-striatal slice used to study endogenous neurogenesis or viral vector-mediated 
overexpression of -synuclein in midbrain slices. We discuss the possibility of using such 
models to induce adult neurogenesis by combining pharmacological treatments or for 
preclinical studies in cell transplantation.  
The strategies in place thus far to restore the dopaminergic system in PD are 
pharmacological treatments, such as administration of L-DOPA, cell restorative therapy by 
gene therapy, or cell therapy by stem cell grafting. The main pharmacological treatment for 
PD symptoms today is the administration of L-DOPA, especially in the first stages of 
disease. L-DOPA, a DA precursor, acts to counteract the DA deficit in neurons. However, 
the beneficial effect of the drug lasts only a few years with disease progression and loss of 
efficacy, followed by onset of secondary effects such as on–off phenomena, dyskinesia, and 
psychosis. Moreover, recent studies in an animal model (Muller et al., 2004) suggest a toxic 
effect of prolonged L-DOPA treatment; thus, pharmacological investigation is devoted to 
studying new compounds or new therapeutic strategies. Inhibitors of an alternative 
metabolic route of DA such as entacapone and tolcapone are also used in pharmacological 
treatment (Linazasoro, 2008).  
The administration of several neurotrophic factors has been intensively investigated in a rat 
model as a possible therapeutic strategy for PD (Grandoso et al., 2007). In particular, glial 
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cell line–derived neurotrophic factor (GDNF) has been shown to exert prominent action on 
dopaminergic neurons by enhancing their survival and stimulating the outgrowth of DA 
fibers (Kirik et al., 2004). As noted, current pharmacological therapy for PD is considered 
only palliative and not curative, reflecting the necessity for new strategies and new 
therapeutic targets. 
The principal targets of gene therapy in PD are replacement of tyrosine hydroxylase (TH) 
striatal neurons and blocking of neurodegeneration of the nigrostriatal pathway. The latter 
can be accomplished with local expression of neuroprotective neurotrophins such as GDNF. 
One promising approach to gene therapy for PD is the combined use of craniotomy as a 
delivery system with viral vectors as a gene expression system. Injection of viral vectors for 
the expression of neurotrophic factors in primate models allows local production of 
therapeutic genes. Nevertheless, the single injection into the human or animal brain of either 
adeno-associated virus (AAV) or herpes simplex virus results in an inflammatory reaction 
leading to astrogliosis and demyelination (Dewey et al., 1999; McMenamin et al., 1998). Both 
AAV and retrovirus permanently and randomly integrate into the host genome, but neither 
AAV nor retrovirus crosses the blood–brain barrier (BBB). Therefore, it is necessary to 
administer the virus via craniotomy and by intracerebral injection, a very invasive approach. 
However, the most intense expression of the therapeutic gene is generally limited to the 
injection site, owing to limited diffusion of the virus within the brain. Current limitations of 
brain gene therapy approaches can be circumvented with the development of a 
transvascular delivery as a support for gene therapy. However, this approach would require 
the formulation of plasmid DNA in a way that allows the exogenous gene to cross the BBB 
and enter the brain via the transvascular route after an intravenous injection. 
Cell therapy for PD is based on neural stem cell transplantation intended to give rise to new 
dopaminergic neurons. The in vitro features of stem cells include the ability to (1) proliferate 
in a 3D free-floating system called neurospheres, (2) exhibit self-renewal, (3) generate a large 
number of progeny through the transient amplification of a population of progenitor cells, 
and (4) retain their multi-lineage potential over time. These cells must generate new cells in 
response to injury or disease, create synapses, and integrate into a preexisting neuronal 
network. Cells that satisfy all of these criteria are defined as stem cells, whereas those cells 
that satisfy some but not all of the functional criteria listed above and are already committed 
to one specific lineage are defined as progenitor cells. From a clinical point of view, cell 
therapy in PD must satisfy the following objectives:  (1) the grafted cells must survive and 
form connections; (2) the patient's brain must integrate and use the grafted neurons; and (3) 
the grafts must induce measurable clinical improvement (Lindval & Bjiorklund, 2004; Meyer 
et al., 2010). 
Cell regeneration can be obtained also by pharmacological activation of endogenous 
neurogenesis. Generation of newborn neurons in the adult mammalian brain occurs 
throughout life in the subventricular zone (SVZ) or in the subgranular zone of the 
hippocampus. In particular, the SVZ cover an interesting role in new cell regeneration due 
to the proximity with striatum. Neurogenesis can occur in brain regions which are damaged 
due to pathological conditions; in this case, the local environment influenced by cellular 
stress plays a crucial role in modulating the mechanisms of proliferation, migration and 
differentiation. Adult neurogenesis can be sustained, directly, by activating mechanisms of 
cell regeneration (e.g. with neurotrophic factors), or by the clearance of local negative 
environment (e.g. blocking excitotoxicity and apoptosis) (Vergni et al., 2009) 
Despite problems, the use of cell therapy for the replacement of dead neurons results an 
attractive strategy for the treatment of PD. Here we review different in vitro experimental 
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models used to study the cellular mechanisms of PD and highlight  the feasibility of such 
models for each of the use described above (pharmacological treatment, gene therapy or cell 
transplantation). 
2. The advantage of using brain organotypic cultures  
The necessity to cultivate slice tissues begins from the needs to find out a valid and 
reliable model between the monocultures and in vivo models. The organotypic culture 
resembles the in vivo model better than dissociated cultures. In fact, individual cells are in 
tight contact with each other, maintain their organotypic architecture, and preserve 
neuron–glia interactions, tissue-specific transport, and ion diffusion systems. Moreover, 
the organotypic cultures represent an efficient cellular model to overcome the in vivo 
impediments of the BBB. The strength of organotypic cultures in neuroscience research 
has been the opportunity to cultivate for weeks or months CNS tissue, giving open 
accessibility to complex cellular systems. Organotypic cultures are ideally prepared from 
P3-P10 animals (rats or mice) even if few attempts have been made to cultivate 
organotypic slices from adult CNS tissues. Young postnatal animals already possess 
essential cytoarchitecture, are easily handy -respect to the embryonic tissue- and nerve 
cells survive explantation more readily –respect to the adult slices. The advantage of use 
organotypic cultures derives from their versatility in experiments that require long-term 
survival, such as live recording (Zhang et al., 2007; Lacar et al., 2010) or pharmacology 
(chronic drug application) as well as electrophysiology.  
Many different procedures have been proposed to maintain slice tissues from CNS in 
culture, but the most successful was the “roller tube” technique. This technique, finally 
characterized more in detail by Gaehwiler (1988), was developed on the basis of 
experiences based on multitude of works with explants culture.  
In roller tube cultures (Fig. 1A), the tissue is embedded in a plasma clot and attached on a 
glass coverslip. The coverslip with the embedded slice tissue are located in a tube that 
undergoes continuous slow rotation in a cell culture incubator. The oxygenation is 
maintained by continuous exchange of liquid-gas interface generated by the slow rotation. 
The technique was successively modified several time (e.g. Braschler et al., 1989; Andres et 
al., 2005) but the roller tube technique always maintain a very thin cultures (from an initial 
400m to about 50m) with consequential preferential use for experiments that require 
optimal optical conditions (e.g. electron microscopy or electrophysiology).   
At the beginning of 90’s Stoppini and colleague (1991) published a new method to 
cultivate organotypic slices. In this method brain slices were placed on a semiporous 
membrane and cultivated at the air-liquid interface (fig. 1B). The absence of clot facilitates 
the studies of synaptic reorganization being a useful tool to study plasticity and sprouting 
already during the first days of culture. The real advantage of this technique is that 
cultures are easily prepared and offer great advantages when a 3D structure is desired 
(from an initial 400m thickness, slices are cultivated up to 100-150m). The air-liquid 
interface has become a key instrument to study the adult neurogenesis. Organotypic 
cultures match the tri-dimensional space where neural progenitors migrate to reach 
maturation in vivo. In the paper by Vergni and colleagues (2009) the authors ideally 
represented the slice culture comprising subventricular zone (SVZ), as the spatial 
extension to elaborate a mathematical model to describe neuroblast activation and 
migration following oxygen and glucose deprivation.    
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Fig. 1. Roller tube (A) and semiporous membrane (B) methods used to cultivate 
organotypic cultures. In both cases slices are cultivated in air-liquid interface, generated by 
tube rotation (A) or by the membrane (B) (see text for explanation). 
3. Organotypic models for parkinson’s disease 
The first organotypic models used to study the nigrostriatal pathway were developed as co-
cultures of slices from the substantia nigra with cortex and striatum (Ostergaard et al., 1996; 
Plenz & Kitai, 1998). These organotypic co-cultures, cultivated with using the roller tube 
method as well as a semiporous membrane, after several days in culture developed 
dopaminergic fibers connecting the substantia nigra with the striatum. Preservation of 
function of the newborn fibers was demonstrated by electrophysiology whereas the 
anatomical connection was shown by immunofluorescence. These organotypic models were 
used to study the role and the modulation of glutamate in dopaminergic development 
(Gramsbergen et al., 2002; Ostergaard et al., 1996; Plenz & Kitai, 1998). By confocal laser 
scanning microscopy, Plenz and Kitai demonstrated that the glutamate system modulated 
the dopaminergic innervations of the striatum. Activation of glutamate receptors generated 
sprouting of dopaminergic fibers and increase of innervations in the striatum. First was 
hypothesized that activation of glutamatergic receptors could induce neurogenesis but no 
generation of new neurons was observed in the substantia nigra. Increase of striatal neurons 
innervations was explained as a trophic effect generated by the selective activation of the 
metabotropic receptors of the mGluR group I, as specific mGluR I antagonists inhibited the 
dopaminergic innervation in the striatum. Results are sustained also by the mRNA 
expression of mGluR5 and mGluR5 receptor (Testa et al., 2005; Romano et al., 2005). Because 
both drugs were added to the medium, no conclusions could be drawn as to the site of drug 
action. In this case the stereotaxic application of the drug (see below Stahl et al., 2009) may 
account for a more precise evaluation of the mechanism. 
The relevance of the co-culture was addressed later with studies of the effect of donor age 
on dopaminergic innervations (Gramsbergen et al., 2002). Because the model is composed of 
three different slices (co-culture), the age of the tissue donor is relevant to slice preservation 
and dopaminergic innervation. Of interest, it was found that the addition of brain-derived 
neurotrophic factor (BDNF) had a trophic effect and stimulated an increase in TH 
immunoreactivity in the striatum as well as protection from apoptotic death. BDNF also 
induced an increase in cell generation, possibly of progenitor cells, expressing TH 
immunoreactivity. These observations indicated that BDNF may sustain cell viability and 
dopaminergic differentiation after grafting of immature DA neurons. 
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PD in these slices can be modeled by treating organotypic cultures with toxins, selective for 
DA nigro-striatal degeneration (6-hydroxy DA-6-OHDA, rotenone, MPTP). As in animal 
model, 6-OHDA in organotypic cultures drives to neuronal death mediated by oxidative 
stress (Saner et al., 2007) inducing selective degeneration of dopaminergic neurons. 
However, this toxin doesn’t produce extra-nigral pathology or Lewy body–like inclusions 
(Lane et al., 2007). In order to set up an organotypic culture as a model of PD it is important 
to take in account how to apply the toxin. Evaluation of neuronal death is different 
depending on the method of 6-OHDA application (Stahl et al., 2009). If toxin is applied 
directly in the medium it generates uniform DAergic cell death without accounting for 
natural variation occurring among slices, whereas local application of the drug at the tissue 
surface of main dopaminergic nuclei (substantia nigra pars compacta, ventral tegmental 
area and retrorubral field) of organotypic cultures, cause a precisely localized cell death 
resembling in vivo stereotactic model (Stahl et al., 2009). 
 Recently, we proposed an innovative organotypic model to study nigrostriatal degeneration 
and adult cell regeneration (Cavaliere et al., 2010). The presence of the nigrostriatal network 
with the cortex and subventricular zone (SVZ) in a single slice made possible the study of 
the mechanisms of nigrostriatal degeneration as well as the mechanisms of adult 
neurogenesis from the SVZ. This type of slice was made by cutting in a single plane the 
region between the ventral mesencephalon and the cortex (Fig. 2).  
 
 
Fig. 2. Schematic view of organotypic slice preparation preserving the nigrostriatal 
pathway.  Slices are cut (350m) at 45º in a single plane to include the substantia nigra (sn), 
striatum-caudate putamen (cp), subventricular zone of the lateral ventricle (lv), and cerebral 
cortex (cx). 
In this model, nigrostriatal degeneration can be obtained by mechanical transection of 
nigrostriatal fibers or chemically, for example by treatment with the DA analog 6-OHDA. In 
both cases, in agreement with the results presented by Gramsbergen and colleagues (2002), 
the degeneration of the nigrostriatal network induced classic PD features (e.g. -synuclein 
inclusions, Halliday and McCann, 2008) and increase in TH expression in the neurogenetic 
niche of the SVZ.  It is still not clear whether the increment of TH in SVZ cells means an 
increment in protein synthesis or generation of newborn TH+ cells, but the functional 
meaning seems to be a response to the damage generated in the striatal area.  
PD can also be modeled in organotypic cultures from cortex-striatum and SVZ (Cavaliere et 
al., 2005; Vergni et al., 2009; Tønnesen et al., 2011; Fig.3) in which dopaminergic inputs from 
the substantia nigra to the striatum are severed by slicing. This model is extremely useful 
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especially in studying neurogenesis induced after severe nigro-striatal degeneration. 
Tønnesen and colleagues (2011) used this model to study functional graft of multipotent 
stem cells in damaged striatum. It is well known that effective synaptic integration into pre-
existing neuronal circuitry after stem cell transplantation results difficult to analyze despite 
integration in the host tissue and robust behavioral rescue (Parish et al., 2008). In this paper 
the authors overexpressed the gene Wnt5a into TH-GFP derived neurospheres to generate 
DA neurons. These cells were then transplanted in the cortex-striatum-SVZ organotypic 
model and patch clamp recording and optogenetic tools were used to study the functional 
properties and synaptic integration of transplanted DA neurons into host cells. Host brain 
tissue was modified genetically to respond to optogenetic stimuli. Briefly, optogenetic is the 
response, in milliseconds time-scale, of cells overexpressing foto-sensitive receptors, like 
channelrhodopsins (ChR) or halorhodopsin (NpHR). Cells modified in this way can be 
depolarized (in case of ChR) or hyperpolarized (in case of NpHR) when stimulated with 
blue or orange light respectively (Miesenböck G. 2009). Optogenetic stimulation of 
organotypic slices and patch clamp recording of GFP grafted cells revealed synaptic 
integration and bidirectional connection of grafted cells with cortex and striatum.  
 
 
Fig. 3. Schematic view of cortex-striatum and SVZ organotypic slice. Slices are cut (350m) 
coronally in a single plane to include the striatum-caudate putamen (cp), subventricular 
zone of the lateral ventricle (SVZ), cerebral cortex (cx) and corpus callosum (cc) and 
cultivated in air-liquid interface. 
Organotypic cultures were used also to study the effect of-synuclein on midbrain neurons. 
This model resembles the animal model obtained by viral transduction of human -
synuclein in rodents or non human primates (Kirik et al., 2002, 2003; Eslamboli et al., 2007). 
Differently from the methods that use drug delivery, this model doesn’t address free radical 
damage and associated mitochondrial dysfunction, moreover the neurotoxin models are 
essentially non-progressive and do not replicate all aspects of the disease. This model takes 
advantage of the special property of recombinant vectors generated from adeno-associated 
viruses (rAAV) to transduce the nigral dopamine neurons with very high efficiency. In the 
organotypic model, midbrain slices were trasfected with truncated α-synuclein (A53T) fused 
to EGFP (Zach et al., 2007). Virus exposure resulted in dramatic changes in neurite 
morphology with -synuclein locally accumulated in distorted and swollen neuritis. 
Neuritic swelling was observed especially in long neurites originating from putative 
projection neurons transduced with truncated more than with the full-length α-synuclein, as 
already demonstrated in animal model and PD patients. 
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4. Advances of preclinical cell therapy  
Different cell types have been used for experimental and clinical cell therapy, giving in all 
cases partial PD symptom improvement. Neurospheres from human fetuses have already 
been used for PD cell therapy (see Brundin et al., 2000, and Lindval & Kokaia, 2006, 2009, for 
a review). They consist of both multipotent stem cells and more restricted progenitors at 
different stages of differentiation. Kim and colleagues in 2006 performed a comparative 
study between neurospheres obtained from different fetal brain tissues, in order to check 
whether the neural stem and precursor cells have specific regional or temporal 
characteristics with regard to growth, differentiation, and region-specific gene expression. 
They found that isolated neurospheres from different CNS compartments expressed 
distinctive molecular markers of regional identity even if this regional pattern could be 
reversed by environmental factors.  
Transplantation studies in animal models of PD have highlighted the main problems that 
arise from the stem cell grafts (Table 1 ). In line with this the preclinical use of organotypic 
tissue model to study mechanisms and cell regeneration in PD becomes worthy. 
In most cases, grafted cells displayed many of the morphological characteristics of DA 
neurons, with expression of dopaminergic markers and reinnervation of the lesioned 
striatum. However, cell therapy presents secondary effects. First, the risk of teratoma from 
embryonic and fetal stem cell transplantation is relatively high. It has to be considered that 
direct implantation of mouse embryonic stem cells into the rat striatum gives rise to tumor 
generation in 20% of the cases (Freed et al., 2001). Second, in 15% of the patients 
transplanted with stem cells of fetal origin, post-operative dyskinesias have been observed 
in the “off” phase (Bjorklund et al., 2002).  In fact, the most important problem with the use 
of human fetal stem cells, besides the poor availability, is the lack of standardization, which 
results in a high variability in the degree of symptomatic relief.  
 
CELL  REINNERVATION SYMPTOMS 
IMPROVEMENT 




Partial Partial Risk of teratoma 
Ethical considerations 




Partial Partial Risk of teratoma 
Ethical considerations 
Sanchez-Pernaute 
et al., 2008 
Human 
ESC 
Not detected Partial Risk of teratoma 
Ethical considerations 




Fibers Partial Lack of homogeneous 
differentiation, no 
 evidence of dopaminergic 
specialization, low 
integration into pre-existing 
neuronal network 
Dezawa et al., 
2004 
EMT Extensive Partial Ethical considerations, Lack 
of homogeneous 
differentiation 
Winkler et al., 
2000 
Table 1. Stem cell graft in animal models of PD. ESC, embryonic stem cells; BMSC, bone 
marrow stem cells; EMT, embryonic mesencephalic tissue.  
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To overcome the secondary effects of using embryonic and fetal stem cells, several groups 
have used adult stem cells for transplantation located primarily in the SVZ of the forebrain 
and in the sub-granular layer of the dentate gyrus of the hippocampal formation (Vergni et 
al., 2009).  However, newly generated cells with a neuronal phenotype can be generated also 
from adult tissues that are different from the brain. Because of the ease of their isolation and 
their large potential for differentiation, mesenchymal stem cells are among the first stem cell 
types to be introduced into clinical studies. Results on differentiation of mesenchymal stem 
cells derived from such tissues are still controversial; e.g., debate persists about how to 
isolate a homogeneous population of the cells with specific criteria from the bone marrow, 
how to expand them ex vivo without affecting their differentiation potential, and how to 
develop easy methods for quality control of the cellular-based products (Chen et al., 2006; 
Kassem, 2006). 
In addition to the use of the correct cell type (Meyer et al., 2010) and the generation of a 
standard protocol, other scientific improvements are necessary for the development of a 
clinically practicable cell therapy in PD. One is the proper selection of patients. It is of 
primary importance to determine whether a cell graft can be affected by disease 
progression. Cell regeneration should be done especially in those patients who positively 
respond to L-DOPA and in those patients for whom the main pathology is a loss of DA 
neurons, more than debilitating symptoms like dementia or degeneration of the non-
dopaminergic system. In this regard, PET analysis before the engraftment is critical to 
understanding the preoperative degeneration pattern. 
5. Conclusion 
Cell therapy used to generate new dopaminergic neurons possesses a high potential. Up to 
now, all of the therapies used to counteract the symptoms of PD are palliative and limited in 
their therapeutic impact. Furthermore, the lack of standardized protocols and absence of a 
correct selection protocol for patients in the clinical trials result in a high variability in the 
degree of symptomatic relief. More efforts to surmount this variability and to achieve 
success in restorative therapy have to be made in this direction. The selection of a correct 
model to study the cellular and molecular mechanisms and for preclinical investigations 
represents a promising strategy to achieve a successful protocol for animal and human cell 
therapy. 
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